Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04989725 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

Study acronym: SUPPRESS
StatusRecruiting
PhasePhase 2
Started2021-10-01
View on ClinicalTrials.gov ↗

Amendment history

2026-07-21
Study Status, Study Description, Conditions, Outcome Measures, Eligibility v4
Primary completion date2025-12-01→2027-03-01
Completion date2027-12-01→2029-03-01
Eligibility criteria-76 characters
Inclusion Criteria: Age ≥18 years BiopsyMetastatic proven HNSCCcancer (oropharynx,any oral cavity, nasopharynx, sinonasal, larynx or hypopharynxhistology) Metastatic HNSCC, with pathological or radiological proof of metastasis Abil [...]
Secondary endpoints5 entries, revised
Quality of life Measured using the FACT-G tool, head and neck cancer-related patient reported outcome- CTCAE (PRO-CTCAE) and Quality of life 5-level EQ-5D
2023-12-11
Study Status v3
Primary completion date2024-10-01→2025-12-01
Completion date2025-10-01→2027-12-01
2022-11-11
Study Identification, Study Status v2
Study title-3 characters
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Head and NeckMetastatic Cancer
2022-03-06
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2021-07-30
Original filing
A registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Trial Details
NCT Number NCT04989725
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Conditions Metastatic Cancer, Oligoprogressive
Enrollment 46 participants
Start Date 2021-10-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-22